Haematologica

Haematologica www.haematologica.org publishes novel findings in basic, clinical and translational hematology research. Impact Factor (JCR) 7.116 (7th of 76)

Haematologica/The Hematology Journal (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE, www.icmje.org) recommendations on publication ethics policies for medical journals. Haematologica was founded in 1920 by Adolfo Ferrata

Perspective Articles: Spleen volume reduction has long been a key endpoint in randomized controlled trials in myelofibro...
06/02/2026

Perspective Articles: Spleen volume reduction has long been a key endpoint in randomized controlled trials in myelofibrosis.
Find here a critical review of the limitations of relying on spleen response alone and the reason for a broader, more patient-centered approach to clinical trial design. By integrating symptoms, quality of life, biological markers, and long-term outcomes, the authors discuss how future trials can better capture meaningful clinical benefit and guide therapeutic decision-making in myelofibrosis.
https://haematologica.org/article/view/12296

Review article: Over the past decade, clonal hematopoiesis of indeterminate potential (CHIP) has reshaped our understand...
04/02/2026

Review article: Over the past decade, clonal hematopoiesis of indeterminate potential (CHIP) has reshaped our understanding of blood aging and disease risk.
A new review traces the key discoveries that revealed how somatic mutations in hematopoietic stem cells drive clonal expansion, linking CHIP not only to hematologic malignancies but also to cardiovascular disease, inflammation, and overall mortality.
https://haematologica.org/article/view/12249

infectious risks linked to emerging immune-based treatments: a severe viral complication during novel immunotherapy in a...
31/01/2026

infectious risks linked to emerging immune-based treatments: a severe viral complication during novel immunotherapy in a case of progressive multifocal leukoencephalopathy and BK virus–associated nephropathy occurring during bispecific antibody therapy for multiple myeloma.
https://haematologica.org/article/view/12934

Infection or malignancy? The first reported case of transient peripheral monoclonal plasmacytosis in a patient with endo...
30/01/2026

Infection or malignancy? The first reported case of transient peripheral monoclonal plasmacytosis in a patient with endocarditis: a reminder of how inflammation and infection can blur hematologic boundaries.
https://haematologica.org/article/view/12258

The case of an 80-year-old man offers an important contribution to understanding a rare diagnostic and biological associ...
29/01/2026

The case of an 80-year-old man offers an important contribution to understanding a rare diagnostic and biological association between histiocytic and myeloid disorders. This report describes ALK-positive histiocytosis occurring alongside a clonally related chronic myelomonocytic leukemia, offering new insights into shared disease origins and myeloid neoplasia evolution.
https://haematologica.org/article/view/12274

A rare and devastating complication after CAR T-cell therapy in multiple myeloma. The case of a man with extensive non-c...
28/01/2026

A rare and devastating complication after CAR T-cell therapy in multiple myeloma. The case of a man with extensive non-clonal CAR T-cell expansion leading to a fatal hyperinflammatory syndrome, with overlapping immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, cytokine release syndrome, and neurotoxicity.
https://haematologica.org/article/view/12242

What molecular pathways support the growth and survival of Dnmt3a;Npm1-mutant acute myeloid leukemia (AML)? A study by C...
27/01/2026

What molecular pathways support the growth and survival of Dnmt3a;Npm1-mutant acute myeloid leukemia (AML)? A study by Colom Díaz and colleagues investigates the role of Metallothionein 1, shedding light on disease biology and uncovering potential vulnerabilities in this genetically defined subtype of AML.
https://haematologica.org/article/view/12214

Can dual-targeted CAR T-cell therapy improve outcomes in one of the most challenging subtypes of pediatric B-cell acute ...
26/01/2026

Can dual-targeted CAR T-cell therapy improve outcomes in one of the most challenging subtypes of pediatric B-cell acute lymphoblastic leukemia (B-ALL)? This study focuses on CD19- and CD22-targeted CAR T cells in children with TCF3–HLF–positive relapsed/refractory B-ALL, addressing key questions on feasibility, response, and long-term disease control.
https://haematologica.org/article/view/12070

Can early identification and management of extracranial arteriopathy influence long-term neurological outcomes in sickle...
25/01/2026

Can early identification and management of extracranial arteriopathy influence long-term neurological outcomes in sickle cell anemia? A new long-term prospective cohort study explores the relationship between vascular disease and silent cerebral infarcts, addressing key questions on screening, monitoring, and clinical management.
https://haematologica.org/article/view/12140

Safety and feasibility of venetoclax–obinutuzumab in everyday clinical practice for chronic lymphocytic leukemia (CLL): ...
23/01/2026

Safety and feasibility of venetoclax–obinutuzumab in everyday clinical practice for chronic lymphocytic leukemia (CLL): a new study challenges conventional assumptions, showing that non-traditional factors may significantly influence feasibility and safety of this fixed-duration regimen in patients with CLL.
https://haematologica.org/article/view/12141

What are the real-world hematologic and infectious risks after CAR T-cell therapy in multiple myeloma? Dima and colleagu...
22/01/2026

What are the real-world hematologic and infectious risks after CAR T-cell therapy in multiple myeloma? Dima and colleagues explore cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated patients with relapsed or refractory multiple myeloma.
https://haematologica.org/article/view/12172

Indirizzo

Via Giuseppe Belli 4
Pavia
27100

Orario di apertura

Lunedì 09:00 - 18:00
Martedì 09:00 - 18:00
Mercoledì 09:00 - 18:00
Giovedì 09:00 - 18:00
Venerdì 09:00 - 18:00

Telefono

+39038227129

Sito Web

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Haematologica pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Haematologica:

Scelte rapide

Promuovere

Condividi

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram